Your online Gateway to Ropack Inc. in 2011
10801 Mirabeau Street,
Montreal QC H1J 1T7
513 846-0921
www.ropack.com
About Ropack Inc.
Watch our video
Ropack offers turnkey primary and secondary pharmaceutical packaging services of solid oral dosages, tablets, powder, and encapsulation into blisters, pouches, bottles, stick packaging and carded blisters. Ropack recently added syringe assembly and vial labeling capabilities. Facilities are cGMP compliant, FDA certified and have 25 Class 100000 production rooms. Ropack is competitive, flexible and agile, supporting clinical trials, short-run start-ups, commercial production for more than 100 U.S., Canadian and European pharmaceutical customers.
Ropack has more than ten years of experience packaging temperature- and humidity-sensitive materials. Our proven record of accomplishment in new product launches will support and accelerate your go-to-market timeline.
See what's new from Ropack's turnkey primary and secondary pharmaceutical and nutraceutical packaging services, including the latest advancements in blisters at Interphex 2011.Now Ropack offers stick packaging – slim, tube-shaped uni-dose packaging of solid oral dosage in a low relative humidity, controlled residual oxygen and temperature-controlled environment. Stick packaging is popular in Japan and Europe for its accuracy and convenience, and now Ropack is advancing stick packaging technology in North America.
Ropack now offers manufacturing and packaging environments to meet even the most exacting specifications. A new 15,000-square-foot dedicated production suite is temperature-controlled with low RH (20%) and controlled residual oxygen (< 2%). Like all Ropack facilities, it is cGMP compliant, FDA certified and Health Canada approved.
Ropack Enhances Services with Controlled Production Environment
For more information:
To schedule a meeting, call or text Paul Dupont, Director of Business Development, at 513 846-0921, or email him: paul.dupont@ropack.com.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.